Cell therapy (CAR-T) · Kills target cells, directed at CD70 · developed by CRISPR Therapeutics
CTX131 is an allogeneic T-cell therapy in which donor T lymphocytes are gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and engineered to express a chimeric antigen receptor specific for CD70. The CAR T-cells recognize and bind CD70-overexpressing tumor cells, leading to cytotoxic T-lymphocyte-mediated killing. It is being studied in T cell lymphoma, B cell lymphoma, and acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06492304 | Phase 1 | T Cell Lymphoma | Completed | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaB Cell LymphomaT Cell Lymphoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →